Synthesis of polyamides from diamines of the fluorene series

Aromatic polyamides were prepared by polycondensation of isophthaloyl chloride and 2,7-diaminofluorene, 2,7-dimainofluorenone, or 2,5-diaminofluorenone in AcNMe2 or N-methyl-2-pyrrolidinone at 20 deg - 30 deg for 1.5-2 hr. Isophthaloyl chloride-2,5-diaminofluorenone copolymer 39609-29-51 was sol. in AcNMe2, N-methyl-2-pyrrolidinone, DMF, and hexamethylphosphoramide, whereas isophthaloyl chloride-2,7-diamino-fluorene copolymer 39609-30-3 and isophthaloyl chloride-2,7-diamino-fluorenone copolymer 39609-31-0 were not sol. in the solvents cited. The aromatic polyamides revealed thixotropic properties in 0.5% solutions in H2SO4

Synthesis of some flurophenyl 4-oxocyclopentane[d]isoxazolines and their dioxolane derivatives

A number of new fluorophenyl 4-oxocyclopentane[d]isoxazolines and their dioxolane derivatives has been synthesized. The obtained substances are of the interest as the perspective biologically active compounds as well as the intermediates in total synthesis of fluorinated prostaglandin analogues

trans-Hydroxylation of cyclopent-5-ene[d]isoxazolines

The title reaction has been studied as a variant of the cyclopentane ring functionalization of cyclopent-5-ene[d]isoxazolines as the key intermediates in total synthesis of azaand oxo prostaglandin analogues by nitrileoxides approach. The oxidation, epoxides cleavage and hydrolysis of obtained monoesters and/or acylation lead with good yields to trans-5,6-dihydroxycyclopentanoisoxazolines or their acyl derivatives. The synthesized substances are the intermediates in total synthesis of prostaglandin analogues, as well as perspective biologically active compounds

Synthesis and reductive cleavage of 3-(2-flurophenyl) and 3-(4-flurophenyl)-cyclopent-5-en[d]isoxazolines by raney nickel in trifluroacetic acid

3-Fluoro arylcycloopent-5-en[d]isoxazolines have been obtained via the 1,3-dipolar cycloaddition of cyclopentadiene to aromatic nitrile oxides. The reductive cleavage of these isoxazolines by Raney nickel in trifluoroacetic acid led to corresponding acylcyclopentenes along with acylcyclopentanes. The synthesized compounds are the precursors of new prostanoids as well as the analogues of cyclic ?-triketones with fluorinated acyl side chain

Synthesis of (2-fluorophenyl) and (4-fluorophenyl)-(2-nitromethyl)-methanones as precursors of fluorinated prostanoids

The synthesis of new fluorinated primary nitrocompounds ?(2-fluorophenyl)and (4-fluorophenyl)-(2-nitromethylcyclopentyl)methanones has been realized by the nitromethane 1,4-addition to 1-acylcyclopentenes, available by the reductive cleavage of corresponding cyclopent-5-en[d]isoxazolines. The obtained nitrocompounds are the precursors of new fluorinated prostaglandin analogues, which could be synthesized via the formation of second prostanoids side chain by nitrile oxides method

The oxidized bitumens from the modified raw materials

The effect of modification of tar by iron (III) stearate on the rate of the oxidation process and the quality of oxidized bitumen has been studied. The dependences of the softening temperature of bitumen upon the oxidation time, the dynamic viscosity of bitumen on the temperature have been obtained. Penetration, penetration index, group composition and thermal-oxidative stability of oxidized bitumen modified by iron (III) stearate have been determined. It was determined that small quantities of a modifier (up to 1.5 wt %) in the raw material don’t influence the rate of oxidation, and with increasing content of the modifier in the raw material the rate of the process is increased by 1.6–4.0 times

The catalytic hydrogenation of 3-(2-fluorophenyl)- and 3-(4-fluorophenyl)-4,4-ethylenedioxycyclopenta[d]isoxazolines

The catalytic hydrogenation of 3-(2-fluorophenyl)- and 3-(4-fluorophenyl)-4,4-ethylenedioxycyclo-penta[d ]isoxazolines led with good yields to corresponding fluorinated β -hydroxyketones. The synthesized compounds are precursors of new fluorinated prostanoids and carbocyclic analogs of acetogenins being of great interest as potential bi ologically active substances as well

MONO- AND MIXED-HERPESVIRUS INFECTIONS: ASSOCIATION WITH CLINICAL SYNDROMES OF IMMUNODEFICIENCY

In recent years, the number of hard diagnosed, polysymptomatic and polysyndrome conditions and diseases caused by mono- and mixed-herpes infections has sharply increased in the practice of physicians of all specialties. The clinical aspects of the close attention of physicians, virologists and epidemiologists to this viral family are due not only to the onset of atypical forms of these infections, but also to the emergence of the relative new concept of “active chronic atypical infection” caused by herpesviruses and in particular the Epstein-Barr virus. We observed 198 people of both sexes aged between 23 and 60 years, suffering from mono- and mixed herpetic infections (EBV, CMV, HSV 1/2, and HSV type 6). 36% of these, suffered from mono-herpesvirus infections, mixed-herpesvirus infections were diagnosed in 63.7% of cases. A study of functioning characteristics of antiviral protection system as well as defects and disorders in the system of interferons was carried out in patients suffering from various mono-, mixed herpes virus infections and bacterial co-infections. The main clinical syndromes associated with these herpetic infections, as well as prevailing nosological forms of concomitant diseases were revealed. The revealed clinical syndromes and functioning characteristics of an antiviral protection will allow developing of a conceptual, individualized, etio- and immunopathogenetic therapy

ВРОЖДЕННЫЕ И ПРИОБРЕТЕННЫЕ ИНТЕРФЕРОНОПАТИИ: ДИФФЕРЕНЦИРОВАННЫЕ ПОДХОДЫ К ИНТЕРФЕРОНКОРРЕКТИРУЮЩЕЙ ТЕРАПИИ

Various disturbances in the interferon system (IFN) — interferonopathy are considered. The classification of developed by the author is given. The clinical features of Type I interferonopathy associated with the overexpression of type I interferons in the rare Mendelian genetic diseases, some autoimmune diseases, the immune dysregulation syndrome, are characterized. The developed methods of targeted therapy of type I interferonopathies aimed at blocking overexpression of type I interferons as hyperproduction IFNa are described. Interferonopathies most often occur as IFN deficiency: congenital or acquired IFNa/b and IFNg deficiencies in children and adults who are associated with atypical viral or mycobacterial infections. Patients with congenital IFNa deficiency are shown to have replacement interferon therapy. With the acquired deficiency of IFNa, differentiated interferon-corrective therapy is performed. For replacement and interferon-corrective therapy, it is used with good clinical efficacy, safe, no side effects, recombinant human IFNa2b in combination with antioxidants — VIFERONR.Рассмотрены различные нарушения в системе интерферонов (ИФН) — интерферонопатии. Приводится разработанная автором классификация интерферонопатий. Охарактеризованы клинические особенности интерферонопатии I типа, ассоциированной с гиперпродукцией интерферона альфа — редкие генетические болезни Менделя, некоторые аутоиммунные заболевания, синдром иммунной дисрегуляции. Описаны разрабатываемые методы интерферонкорректирующей терапии. Таргетная терапия интерферонопатий I типа, направлена на блокирование гиперпродукции ИФНa. Наиболее часто встречаются интерферонопатии по типу дефицита ИФН: врожденные или приобретенные дефициты ИФНa/b и ИФНg у детей и взрослых, ассоциированные с нетипично протекающими вирусными или микобактериальными инфекциями. Пациентам с врожденным дефицитом ИФНa показана заместительная интерферонотерапия. При приобретенном дефиците ИФНa проводится дифференцированная интерферонкорригирующая терапия. Для проведения заместительной и интерферонкорригирующей терапии с хорошей клинической эффективностью используется безопасный, не имеющий побочных эффектов рекомбинантный человеческий ИФНa2b в комбинации с антиоксидантами — ВИФЕРОНR